Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on December 10, 2025, to two newly hired employees.

GlobeNewsWire • Dec 10, 2025

SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery

PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies.

GlobeNewsWire • Dec 4, 2025

Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences

DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December:

GlobeNewsWire • Nov 25, 2025

Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand

DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company's outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to repurchase of a portion of the Notes satisfied a requirement relating to the Company's divestiture of its Fortrea Patient Access and Endpoint Clinical businesses completed in June 2024. Fortrea's purchase of the tendered Notes on November 21, 2025, reduced the principal outstanding on the Notes from $570,000,000 to $494,257,000.

GlobeNewsWire • Nov 24, 2025

Fortrea Appoints Agnieszka Gallagher as General Counsel

DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M.

GlobeNewsWire • Nov 17, 2025

Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer

DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately.

GlobeNewsWire • Nov 12, 2025

Fortrea Holdings Inc. (FTRE) Q3 2025 Earnings Call Transcript

Fortrea Holdings Inc. ( FTRE ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Tracy Krumme - Senior VP of Investor Relations Anshul Thakral - CEO & Director Jill McConnell - Chief Financial Officer Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division David Windley - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jenny Cao - Truist Securities, Inc., Research Division Alan Chen Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Nov 5, 2025

Fortrea Reports Third Quarter 2025 Results

For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 million GAAP net loss of $(15.9) million Adjusted EBITDA of $50.7 million GAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectively Book-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 months Cost saving initiatives remain on track Raising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today reported financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 5, 2025

Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago.

Zacks Investment Research • Nov 5, 2025